PTO/SB/08a (09-06) Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE d to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

Complete if Known Application Number 10/626,415 Filing Date July 23, 2003 First Named Inventor Karl H WEISGRARER Art I Init 1657 Examiner Name Kailash Srivastava Attorney Docket Number UCAL-282

(Use as many sheets as necessary) Sheet

U.S. PATENT DOCUMENTS Examine Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where No. MM-DD-YYYY Relevant Passages or Relevant Applicant of Cited Document Number-Kind Code² (if known) Figures Appear /K.S./ US-2002/0009439 01-24-2002 MAHLEY et al. IIS. USus. US ŭSus. US-US-US-US-US-US. US.

FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No.1	Foreign Patent Document Country Code ³ Number ⁶ Kind Code ⁸ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°		
						<u> </u>		

Examiner	/Kailash Srivastava/	Date	03/05/2008
Signature	71 talladir diri adiara	Considered	00/00/2000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. § Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. § Applicant is to place a check mark here if English Janguage Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known Substitute for form 1449B/PTO Application Number 10/626,415 July 23, 2003 INFORMATION DISCLOSURE Filing Date First Named Inventor Karl H. WEISGRABER STATEMENT BY APPLICANT Art I Init 1657 Examiner Name Kailash Srivastava (Use as many sheets as necessary) Sheet Attorney Docket Number UCAL-282 2 of I

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1					
/K.S./		ACHARYA et al., (2001) Thermal Denaturation Studies of the Isoforms of Human Apolipopotein E, Biophys. J., Vol. 80, page 147a				
/K.S./		MORROW et al., (2002) Apolipoprotein E4 Forms a Molten Globule, J. Biol. Chem., Vol. 277, page 50380-50385				
/K.S./		PILLOT et al., (1997) Specific modulation of the fusogenic properties of the Alzheimer β-amyloid peptide by apolipoprotein E isoforms, Eur. J. Blochem., Vol. 243, pages 650-659				
			-,			
1						
		н.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Date

Considered

03/05/2008

Examiner

Signature

/Kailash Srivastava/

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the

USPT Our process an explication is required by 3r CHF 1.9 and 13.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPT Our process) an application. Confidentially is governed by 35 U.S.C. 12.4 and 37 CFR 1.1.4 This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the including label. And on the amount of time governed to exposible this form and/or supgestions for eviducing this burder, should be sent to the Chief Information Officer, U.S. Patient on the amount of time governed to exposible this form and/or supgestions for eviducing this burder, should be sent to the Chief Information Officer, U.S. Patient and Tradomark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandrie, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionner for Patients, P.O. Box 1450, Alexandrie, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionner for Patients, P.O. Box 1450, Alexandrie, VA 22313-1450.